Skip navigation

Navigate Country-Specific Regulations and Reimbursement Models ● Optimise Stakeholder Collaboration ● Utilise Real-World Data Collection

May 21-22, 2019
  • Amsterdam, The Netherlands

At CBI’s 4th Annual Managed Access Programmes and Accelerated Pathways, join dedicated peers in a call-to-action to address the nuances and complexities of designing and implementing early access programmes to accelerate access to lifesaving therapies. Convene with key stakeholders for an in-depth and meaningful conversation on the implications, prevailing policies and current industry approaches of managed access programmes. Don’t miss the opportunity to share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes around the world.

Join Stakeholders to Collaborate
on Action Steps To:

  • Identify the Value of Managed Access Programmes for Patients
  • Explore the Regulatory Landscape on a Global Level
  • Update on the Facilitation of Access to Approved Drugs in the U.S.
  • Open Discussion — Enhance Collaboration between
    Patient Advocacy Groups and Manufacturers
  • Explore Global Reimbursement Models —
    Highlighting Germany, France, Spain, United Kingdom and Spain
  • Importance and Role of Global Real-World Data Collection within
    Early Access Programmes
  • Operationalize a Successful Managed Access Programme
  • Cross-Collaboration with Local Partners to Run a
    Managed Access Programme
  • Compassion vs. Viability — Ethical Implications to Consider
    When Carrying Out Managed Access Programmes
New for 2019! Choose Between Two Interactive Breakout Summits:

• Real-World Data Collection Summit •
• Orphan Drug and Rare Disease Summit •

Previous Attendee Acclaim:

I learned a tremendous amount and have many new perspectives to bring back to my own work. The conference gave me new insights to considerations related to reimbursement and real-world data generation when planning Expanded Access / Pre-Approval Access programs. I look forward to the opportunity to continue to connect with these colleagues.

Early Patient Access Program Lead, Bristol-Myers Squibb

Great insights from a variety of perspectives including
the patients, regulators and manufacturers,
who all addressed real issues.

Vice President, AmerisourceBergen

Very informative conference.
Great speakers and collaborative meeting!

Associate Director, Amicus Therapeutics

After ten years in the expanded access space, I learned something new and heard a lot from the patient’s perspective.

Associate Director, Expanded Access, TESARO

Managed Access Programmes and Accelerated Pathways

Navigate Country-Specific Regulations and Reimbursement Models ● Optimise Stakeholder Collaboration ● Utilise Real-World Data Collection

At CBI’s 4th Annual Managed Access Programmes and Accelerated Pathways, join dedicated peers in a call-to-action to address the nuances and complexities of designing and implementing early access programmes to accelerate access to lifesaving therapies. Convene with key stakeholders for an in-depth and meaningful conversation on the implications, prevailing policies and current industry approaches of managed access programmes. Don’t miss the opportunity to share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes around the world.

Join Stakeholders to Collaborate
on Action Steps To:

  • Identify the Value of Managed Access Programmes for Patients
  • Explore the Regulatory Landscape on a Global Level
  • Update on the Facilitation of Access to Approved Drugs in the U.S.
  • Open Discussion — Enhance Collaboration between
    Patient Advocacy Groups and Manufacturers
  • Explore Global Reimbursement Models —
    Highlighting Germany, France, Spain, United Kingdom and Spain
  • Importance and Role of Global Real-World Data Collection within
    Early Access Programmes
  • Operationalize a Successful Managed Access Programme
  • Cross-Collaboration with Local Partners to Run a
    Managed Access Programme
  • Compassion vs. Viability — Ethical Implications to Consider
    When Carrying Out Managed Access Programmes
New for 2019! Choose Between Two Interactive Breakout Summits:

• Real-World Data Collection Summit •
• Orphan Drug and Rare Disease Summit •

Previous Attendee Acclaim:

I learned a tremendous amount and have many new perspectives to bring back to my own work. The conference gave me new insights to considerations related to reimbursement and real-world data generation when planning Expanded Access / Pre-Approval Access programs. I look forward to the opportunity to continue to connect with these colleagues.

Early Patient Access Program Lead, Bristol-Myers Squibb

Great insights from a variety of perspectives including
the patients, regulators and manufacturers,
who all addressed real issues.

Vice President, AmerisourceBergen

Very informative conference.
Great speakers and collaborative meeting!

Associate Director, Amicus Therapeutics

After ten years in the expanded access space, I learned something new and heard a lot from the patient’s perspective.

Associate Director, Expanded Access, TESARO